422 related articles for article (PubMed ID: 31783819)
1. Expression of FSCN1 and FOXM1 are associated with poor prognosis of adrenocortical carcinoma patients.
Liang J; Liu Z; Wei X; Zhou L; Tang Y; Zhou C; Wu K; Zhang F; Zhang F; Lu Y; Zhu Y
BMC Cancer; 2019 Nov; 19(1):1165. PubMed ID: 31783819
[TBL] [Abstract][Full Text] [Related]
2. Fascin-1 Is a Novel Prognostic Biomarker Associated With Tumor Invasiveness in Adrenocortical Carcinoma.
Poli G; Ruggiero C; Cantini G; Canu L; Baroni G; Armignacco R; Jouinot A; Santi R; Ercolino T; Ragazzon B; Assie G; Mannelli M; Nesi G; Lalli E; Luconi M
J Clin Endocrinol Metab; 2019 May; 104(5):1712-1724. PubMed ID: 30476173
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological and Prognostic Characteristics of CD276 (B7-H3) Expression in Adrenocortical Carcinoma.
Liang J; Liu Z; Pei T; Xiao Y; Zhou L; Tang Y; Zhou C; Wu K; Zhang F; Zhang F; Yin X; Chen N; Wei X; Lu Y; Zhu Y
Dis Markers; 2020; 2020():5354825. PubMed ID: 31998416
[TBL] [Abstract][Full Text] [Related]
4. Identification of prognostic genes in adrenocortical carcinoma microenvironment based on bioinformatic methods.
Li X; Gao Y; Xu Z; Zhang Z; Zheng Y; Qi F
Cancer Med; 2020 Feb; 9(3):1161-1172. PubMed ID: 31856409
[TBL] [Abstract][Full Text] [Related]
5. Circulating Fascin 1 as a Promising Prognostic Marker in Adrenocortical Cancer.
Cantini G; Fei L; Canu L; De Filpo G; Ercolino T; Nesi G; Mannelli M; Luconi M
Front Endocrinol (Lausanne); 2021; 12():698862. PubMed ID: 34248854
[TBL] [Abstract][Full Text] [Related]
6. Identification of immune-related biomarkers in adrenocortical carcinoma: Immune-related biomarkers for ACC.
Peng Y; Song Y; Ding J; Li N; Zhang Z; Wang H
Int Immunopharmacol; 2020 Nov; 88():106930. PubMed ID: 32919215
[TBL] [Abstract][Full Text] [Related]
7. Construction of a robust prognostic model for adult adrenocortical carcinoma: Results from bioinformatics and real-world data.
Tian X; Xu WH; Anwaier A; Wang HK; Wan FN; Cao DL; Luo WJ; Shi GH; Qu YY; Zhang HL; Ye DW
J Cell Mol Med; 2021 Apr; 25(8):3898-3911. PubMed ID: 33626208
[TBL] [Abstract][Full Text] [Related]
8. Is there a role for epithelial-mesenchymal transition in adrenocortical tumors?
Bulzico D; Faria PAS; Maia CB; de Paula MP; Torres DC; Ferreira GM; Pires BRB; Hassan R; Abdelhay E; Vaisman M; Vieira Neto L
Endocrine; 2017 Nov; 58(2):276-288. PubMed ID: 28887601
[TBL] [Abstract][Full Text] [Related]
9. FSCN1 is an effective marker of poor prognosis and a potential therapeutic target in human tongue squamous cell carcinoma.
Chen Y; Tian T; Li ZY; Wang CY; Deng R; Deng WY; Yang AK; Chen YF; Li H
Cell Death Dis; 2019 May; 10(5):356. PubMed ID: 31043585
[TBL] [Abstract][Full Text] [Related]
10. Analysis of m6A-Related Signatures in the Tumor Immune Microenvironment and Identification of Clinical Prognostic Regulators in Adrenocortical Carcinoma.
Jin Y; Wang Z; He D; Zhu Y; Hu X; Gong L; Xiao M; Chen X; Cheng Y; Cao K
Front Immunol; 2021; 12():637933. PubMed ID: 33746977
[TBL] [Abstract][Full Text] [Related]
11. Identification of an immune-related gene signature as a prognostic target and the immune microenvironment for adrenocortical carcinoma.
Xu C; Qin C; Jian J; Peng Y; Wang X; Chen X; Wu D; Song Y
Immun Inflamm Dis; 2022 Sep; 10(9):e680. PubMed ID: 36039643
[TBL] [Abstract][Full Text] [Related]
12. Investigation of N-cadherin/β-catenin expression in adrenocortical tumors.
Rubin B; Regazzo D; Redaelli M; Mucignat C; Citton M; Iacobone M; Scaroni C; Betterle C; Mantero F; Fassina A; Pezzani R; Boscaro M
Tumour Biol; 2016 Oct; 37(10):13545-13555. PubMed ID: 27468715
[TBL] [Abstract][Full Text] [Related]
13. Reduced expression of ferroportin1 and ceruloplasmin predicts poor prognosis in adrenocortical carcinoma.
Zhu B; Zhi Q; Xie Q; Wu X; Gao Y; Chen X; Shi L
J Trace Elem Med Biol; 2019 Dec; 56():52-59. PubMed ID: 31442954
[TBL] [Abstract][Full Text] [Related]
14. Lower expression of ATM and gene deletion is more frequent in adrenocortical carcinomas than adrenocortical adenomas.
Ye J; Qi Y; Wang W; Sun F; Wei Q; Su T; Zhou W; Jiang Y; Yuan W; Cai J; Cui B; Ning G
Endocrine; 2012 Jun; 41(3):479-86. PubMed ID: 22311173
[TBL] [Abstract][Full Text] [Related]
15. Over expression of DNA damage and cell cycle dependent proteins are associated with poor survival in patients with adrenocortical carcinoma.
Subramanian C; Cohen MS
Surgery; 2019 Jan; 165(1):202-210. PubMed ID: 30413320
[TBL] [Abstract][Full Text] [Related]
16. Expression of glucocorticoid receptor (GR) and clinical significance in adrenocortical carcinoma.
Wu K; Liu Z; Liang J; Zhang F; Zhang F; Wang Y; Lia T; Liu S; Zhu Y; Li X
Front Endocrinol (Lausanne); 2022; 13():903824. PubMed ID: 35992138
[TBL] [Abstract][Full Text] [Related]
17. Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma.
Fenske W; Völker HU; Adam P; Hahner S; Johanssen S; Wortmann S; Schmidt M; Morcos M; Müller-Hermelink HK; Allolio B; Fassnacht M
Endocr Relat Cancer; 2009 Sep; 16(3):919-28. PubMed ID: 19465749
[TBL] [Abstract][Full Text] [Related]
18. Development and Validation of an m6A RNA Methylation Regulators-Based Signature for Predicting the Prognosis of Adrenocortical Carcinoma.
Shen C; Liu J; Yang X; Jiao W; Wang Y
Front Endocrinol (Lausanne); 2021; 12():568397. PubMed ID: 33692753
[TBL] [Abstract][Full Text] [Related]
19. Expression of the zinc-finger transcription factor Snail in adrenocortical carcinoma is associated with decreased survival.
Waldmann J; Feldmann G; Slater EP; Langer P; Buchholz M; Ramaswamy A; Saeger W; Rothmund M; Fendrich V
Br J Cancer; 2008 Dec; 99(11):1900-7. PubMed ID: 19018264
[TBL] [Abstract][Full Text] [Related]
20. Multiplatform computational analysis of mast cells in adrenocortical carcinoma tumor microenvironment.
Baechle JJ; Hanna DN; Sekhar KR; Rathmell JC; Rathmell WK; Baregamian N
Surgery; 2022 Jan; 171(1):111-118. PubMed ID: 34261605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
